The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06).
 
Rebecca Dent
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DKSH; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Novartis; Pfizer; Roche
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; EP biopharma; Haihe Pharmaceutical; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Carlos Barrios
Stock and Other Ownership Interests - CPO; MedSIR; Thummi
Honoraria - Adium Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Aveo (Inst); BioNTech SE (Inst); BMS Brazil (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Exelixis (Inst); Exelixis (Inst); FORTREA (Inst); FORTREA (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ICON Clinical Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Samsung (Inst); Sandoz (Inst); Sanofi (Inst); Servier (Inst); Sremline (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Hans Wildiers
Consulting or Advisory Role - Agendia (Inst); Astrazeneca (Inst); Augustine Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Immutep (Inst); Lilly (Inst); MediMix bv (Inst); Menarini (Inst); Novartis (Inst); NV Hict (Inst); Pfizer (Inst); PSI (Inst); Roche (Inst); Seagen (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Lilly (Inst); Gilead Sciences (Inst)
 
William Jacot
Honoraria - AstraZeneca; BMSi; Daiichi Sankyo Europe GmbH; Eisai; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; BMSi; Daiichi Sankyo Europe GmbH; Eisai; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/Daiichi Sankyo (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Chugai Pharma; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Jun Ke
Employment - AstraZeneca
 
Chindu Govindaraj
Employment - AstraZeneca
 
Maria Schwaederle
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Robert McEwen
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Danielle Carroll
Employment - AstraZeneca/MedImmune; Azeria Therapeutics (I)
Leadership - Azeria Therapeutics (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Azeria Therapeutics (I)
Honoraria - AstraZeneca (I)
Consulting or Advisory Role - Azeria Therapeutics (I)
Research Funding - AstraZeneca (I)
Patents, Royalties, Other Intellectual Property - Patent: Anti-cxc chemokine receptor-2 binding molecules and uses thereof; Patent: Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia; Royalties from Active Motif (I)
 
Aditya Bardia
Consulting or Advisory Role - Alyssum; Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)